ESMO ECCO 2015

2015-09-25 - 2015-09-29
Vienna, Austria

ASCO 2015

2015-05-29 - 2015-06-02
Chicago, United States

ELCC 2015

2015-04-15 - 2015-04-18
Geneva, Switzerland

Bratislava 2014

2014-10-09 - 2014-10-10
Bratislava, Slovakia

ESMO 2014

2014-09-26 - 2014-09-30
Madrid, Spain
Search in Scientific Content:
Date
Filters:
Treatment
5:31

Treatment of cervical cancer in 2024 in the highlight of KEYNOTE-A18 study

Presenter: Remi Nout
ESMO 2024
Adjuvant P
3:33

Adjuvant Pembrolizumab/Chemotherapy Misses DFS End Point in High-Risk Endometrial Cancer, but Benefits dMMR Subgroup

Presenter: Remi Nout
ESMO 2024
Breast can
5:60

Breast cancer, early stage highlights of the ESMO 2024 Congress

Presenter: Ann H. Partridge
ESMO 2024
Setting a
5:24

Setting a new benchmark for ALK+ aNSCLC targeted therapy - report from ESMO2024

Presenter: Tony S.K. Mok
ESMO 2024
POD1UM-303
1:41

POD1UM-303/InterAACT 2: Potentially Practice-Changing Findings in SCAC - report from ESMO2024

Presenter: Dominik P. Modest
ESMO 2024
Neoadjuvan
6:26

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study

Presenter: Peter Schmid
ESMO 2024
PEACE-3 Tr
5:08

PEACE-3 Trial Shows Combination Therapy Improves Survival in Prostate Cancer

Presenter: Silke Gillessen
ESMO 2024
Adding Met
4:05

Adding Metformin to ADT for Patients with mHSPC: Overall Survival Results from the Multi-Arm, Multi-Stage Randomized Platform Trial STAMPEDE

Presenter: Silke Gillessen
ESMO 2024
Breakthrou
4:18

Breakthroughs and challenges in the treatment of head and neck cancer

Presenter: Robert Sifrer
Danube Symposium
HPV-associ
7:16

HPV-associated head and neck cancers

Presenter: Thomas Hoffmann
Danube Symposium
Follicular
12:06

Follicular Lymphoma highlights of the ASH 2023 Congress

Presenter: Carla Casulo
Specialty: Hematology
ASH 2023
Highlights
9:22

Highlights of the ASH 2023 Congress

Presenter: Mikkael Sekeres
Specialty: Hematology
ASH 2023
Present an
14:07

Present and future of Multiple Myeloma management

Presenter: Xavier Leleu
Specialty: Hematology
ASH 2023
Ibrutinib-
5:010

Ibrutinib-Venetoclax Combination Found Effective Against Mantle Cell Lymphoma

Presenter: Michael Wang
Specialty: Hematology
ASH 2023
Real-World
5:20

Real-World Outcomes With Brexucabtagene Autoleucel

Presenter: Swetha Kambhampati
Specialty: Hematology
ASH 2023
Frontline
8:20

Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia - report from ASH2023

Presenter: Adrian Wiestner
Specialty: Hematology
ASH 2023
Effects of
11:15

Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

Presenter: Richard Gray
Specialty: Breast Cancer
Alpelisib
14:48

Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial

Presenter: Dejan Juric
Specialty: Breast Cancer
Lifestyle
8:40

Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates

Presenter: Wolfgang Janni
Specialty: Breast Cancer
Choice of
8:39

Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors

Presenter: Laura Dominici
Specialty: Breast Cancer
Circulatin
10:32

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients

Presenter: Francois-Clement Bidard
Specialty: Breast Cancer
Axillary R
9:45

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer

Presenter: Emiel J. T. Rutgers
Specialty: Breast Cancer
Accelerate
6:19

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

Presenter: Fank Vicini
Specialty: Breast Cancer
A randomiz
10:32

A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

Presenter: Andrea De Censi
Specialty: Breast Cancer
PALLET: A
12:51

PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Presenter: Mitchell Dowsett
Specialty: Breast Cancer
Phase III
9:33

Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint

Presenter: Charles E. Geyer, Jr
Specialty: Breast Cancer
Adjuvant C
8:05

Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer

Presenter: Miguel Martín
Specialty: Breast Cancer
Adjuvant C
7:33

Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy

Presenter: Laura Spring
Specialty: Breast Cancer
Delaying A
5:48

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

Presenter: Zaida Morante
Specialty: Breast Cancer
Low-Dose T
9:12

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Presenter: Andrea De Censi
Specialty: Breast Cancer
Increasing
11:01

Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis

Presenter: Richard Gray
Specialty: Breast Cancer
Phase Ib/I
8:36

Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-positive Advanced Breast Cancer: Results from the PANACEA Study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)

Presenter: Sherene Loi
Specialty: Breast Cancer
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Interrupti
1:17

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

Presenter: Matteo Lambertini
The issue
1:15

The issue of adjuvant vs neoadjuvant treatment

Presenter: Paolo A. Ascierto
The treatm
1:19

The treatment sequence in metastatic melanoma

Presenter: Paolo A. Ascierto
Functional
1:19

Functional Precision Medicine in Oncology

Presenter: Anthony Letai
The first
1:10

The first mRNA cancer vaccine with pembrolizumab minimizes recurrence rate in melanoma tells Jeffrey Weber clinical investigator

Presenter: Jeffrey Weber
Paradigm s
12:05

Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment

Presenter: Federico Cappuzzo
How will t
9:43

How will the current therapeutic options change the treatment of RCC in the daily practice?

Presenter: Camillo Porta
The role o
5:58

The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma

Presenter: David F. McDermott
Treatment
11:50

Treatment intensification in the treatment of prostate cancer

Presenter: Oliver Sartor
Pembrolizu
16:35

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma

Presenter: Stefan N. Symeonides
State of t
6:13

State of the art treatment of bladder cancer

Presenter: Matthew R. Zibelman
First-line
7:41

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer

Presenter: Ken Kato